Business Description
Johnson & Johnson
NAICS : 325412
SIC : 2834
ISIN : US4781601046
Share Class Description:
JNJ: Ordinary SharesTotal Employee Number:
140,800Compare
Compare
Traded in other countries / regions
JNJ.USA0R34.UKJNJ.ArgentinaJNJ.CanadaJNJB34.BrazilJNJ.GermanyJNJ.MexicoJNJ.Peru1JNJ.ItalyJNJ.AustriaJNJ.SwitzerlandJNJ.ChileJNJ_KZ.KazakhstanJNJ.BulgariaJNJCO.ColombiaJNJ.Ukraine Index Membership
Dow 30S&P 500Russell 1000Russell 3000Dividend KingMSCI World Index IPO Date
1944-09-25Description
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.4 | |||||
Equity-to-Asset | 0.4 | |||||
Debt-to-Equity | 0.68 | |||||
Debt-to-EBITDA | 1.63 | |||||
Interest Coverage | 24.82 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 3.98 | |||||
Beneish M-Score | -2.08 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.9 | |||||
3-Year EBITDA Growth Rate | 19.2 | |||||
3-Year EPS without NRI Growth Rate | 2.1 | |||||
3-Year FCF Growth Rate | 7.2 | |||||
3-Year Book Growth Rate | 4.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 9.21 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.05 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.07 | |||||
9-Day RSI | 51.67 | |||||
14-Day RSI | 55.76 | |||||
3-1 Month Momentum % | 0.32 | |||||
6-1 Month Momentum % | 10.21 | |||||
12-1 Month Momentum % | 53.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.03 | |||||
Quick Ratio | 0.77 | |||||
Cash Ratio | 0.38 | |||||
Days Inventory | 162.44 | |||||
Days Sales Outstanding | 65.44 | |||||
Days Payable | 120.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.05 | |||||
Dividend Payout Ratio | 0.5 | |||||
3-Year Dividend Growth Rate | 4.9 | |||||
Forward Dividend Yield % | 2.1 | |||||
5-Year Yield-on-Cost % | 2.65 | |||||
3-Year Average Share Buyback Ratio | 2.7 | |||||
Shareholder Yield % | 1.98 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 67.82 | |||||
Operating Margin % | 26.77 | |||||
Net Margin % | 21.83 | |||||
EBITDA Margin % | 34.99 | |||||
FCF Margin % | 18.07 | |||||
OCF Margin % | 23.73 | |||||
ROE % | 26.39 | |||||
ROA % | 10.73 | |||||
ROIC % | 14.32 | |||||
3-Year ROIIC % | 64.04 | |||||
ROC (Joel Greenblatt) % | 116.4 | |||||
ROCE % | 18.39 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 9 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 29.35 | |||||
Forward PE Ratio | 21.91 | |||||
PE Ratio without NRI | 24.56 | |||||
Shiller PE Ratio | 31.88 | |||||
Price-to-Owner-Earnings | 36.91 | |||||
PEG Ratio | 2.61 | |||||
PS Ratio | 6.41 | |||||
PB Ratio | 7.52 | |||||
Price-to-Free-Cash-Flow | 35.47 | |||||
Price-to-Operating-Cash-Flow | 27.01 | |||||
EV-to-EBIT | 24.79 | |||||
EV-to-Forward-EBIT | 20.68 | |||||
EV-to-EBITDA | 19.1 | |||||
EV-to-Forward-EBITDA | 17.29 | |||||
EV-to-Revenue | 6.68 | |||||
EV-to-Forward-Revenue | 6.48 | |||||
EV-to-FCF | 36.98 | |||||
Price-to-GF-Value | 1.33 | |||||
Price-to-Projected-FCF | 2.32 | |||||
Price-to-DCF (Earnings Based) | 2.07 | |||||
Price-to-DCF (FCF Based) | 3.07 | |||||
Price-to-Median-PS-Value | 1.33 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.33 | |||||
Earnings Yield (Greenblatt) % | 4.03 | |||||
FCF Yield % | 2.85 | |||||
Forward Rate of Return (Yacktman) % | 13.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:JNJ
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Johnson & Johnson Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 96,362 | ||
| EPS (TTM) ($) | 8.65 | ||
| Beta | 0.0706 | ||
| 3-Year Sharpe Ratio | 0.63 | ||
| 3-Year Sortino Ratio | 1.16 | ||
| Volatility % | 20.67 | ||
| 14-Day RSI | 55.76 | ||
| 14-Day ATR ($) | 5.815566 | ||
| 20-Day SMA ($) | 249.5755 | ||
| 12-1 Month Momentum % | 53.6 | ||
| 52-Week Range ($) | 154.8 - 269.43 | ||
| Shares Outstanding (Mil) | 2,407.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Johnson & Johnson Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Johnson & Johnson Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-13 | In 90 days | ||
| Third quarter earnings results for 2026 | 2026-10-13 | In 90 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-15 08:30 | In 1 day | ||
| Second quarter earnings results for 2026 | 2026-07-15 06:45 | In 1 day | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 10:00 | 232.16 (-0.26%) | ||
| Bernstein’s 42nd Annual Strategic Decisions Conference | 2026-05-27 11:00 | 230.18 (-1.21%) | ||
| USD 1.340000 Cash Dividend | 2026-05-26 | 234.34 (+0.58%) | ||
| Guidance call for 2026 | 2026-05-19 11:30 | 228.92 (+0.97%) | ||
| Guidance call for 2026 | 2026-05-12 14:20 | 221.43 (+0.05%) | ||
| General meeting for 2026 | 2026-04-23 10:00 | 226.10 (-0.04%) |
Show
Entries
Johnson & Johnson Frequently Asked Questions
What is Johnson & Johnson(JNJ)'s stock price today?
The current price of JNJ is $253.85. The 52 week high of JNJ is $269.43 and 52 week low is $154.80.
When is next earnings date of Johnson & Johnson(JNJ)?
The next earnings date of Johnson & Johnson(JNJ) is 2026-07-15.
Does Johnson & Johnson(JNJ) pay dividends? If so, how much?
The Dividend Yield %  of Johnson & Johnson(JNJ) is 2.05% (As of Today), Highest Dividend Payout Ratio of Johnson & Johnson(JNJ) was 0.5. The lowest was 0.43. And the median was 0.46. The  Forward Dividend Yield % of Johnson & Johnson(JNJ) is 2.1%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Johnson & Johnson
Headlines
See More- 1
Jul 14, 2026
Here are the major earnings before the open Wednesday
Seeking Alpha • 5:00pm
Johnson & Johnson: Analysts see upbeat Q2 print despite Stelara headwinds
Seeking Alpha • 11:49am
Jul 08, 2026
Healthcare breadth hits 15-year high, but XLV’s top holdings remain Quant Holds
Seeking Alpha • 6:00am
Jul 02, 2026
Big Pharma gains as U.S. weighs cutting 340B drug discounts
Seeking Alpha • 10:54am
Jun 26, 2026
Lilly, J&J, AbbVie hit new 52-week highs as healthcare outperforms
Seeking Alpha • 11:22am
FDA commissioner contenders down to three - report
Seeking Alpha • 10:18am
Jun 15, 2026
Merck, J&J, Bristol decline on proposed CMS drug price rule
Seeking Alpha • 11:32am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers